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Background: Cellular antiviral activities are critically controlled by transcriptional activation of interferon-inducible
genes, involving interferon regulatory factors (IRFs). Previous data suggested that IRF1 is an activator and IRF2 is a
repressor, which functionally antagonize each other in transcriptional regulation. However, it is not clear how these
two factors function to regulate cellular antiviral activities.
Results: We show that IRF2 is critically required for the induction of the TLR3 and other interferon-inducible genes
in a chromatin environment. While both IRF1 and IRF2 directly interact with the BAF chromatin remodeling complex,
IRF2 is associated with the TLR3 promoter in the unstimulated state and IRF1 binding to the promoter is strongly
induced by stimulation with interferon, suggesting that these two factors may function at different stages of gene
induction in the recruitment of the BAF complex. IRF2 acts to maintain the basal level expression, an open chromatin
structure, and active histone modification marks (H3K9, K14 acetylation and H3K4 tri-methylation) of the TLR3 promoter
in the unstimulated state, while IRF1 serves to rapidly activate the promoter upon stimulation.
Conclusions: IRF1 and IRF2 of the IRF family of transcription factors play distinct roles in cellular response to viral
infection. IRF2 binds to TLR3 and other IFN-inducible gene promoters and maintains an active chromatin structure in
the unstimulated state, which is required for their induction, while IRF1 binding to these promoters activates their
transcription upon viral infection. Thus, the division of labor between the IRF transcription factor family members plays
a pivotal role in coordinating the transcriptional activation in the cellular antiviral response.
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Genome analyses indicate that human genome contains
only about twice the number of genes than the simple
nematode worm, C. elegans, has [1-3]. It has been hypoth-
esized that the more complexity of human compare to the
worm is caused by the diversity of transcriptional regula-
tory DNA elements and transcription cofactor complexes
[4]. Gene duplication in human genome results in the ex-
istence of multiple family members of transcription fac-
tors, which usually have highly conserved DNA-binding* Correspondence: zhangzhy@nwsuaf.edu.cn; zhaok@nhlbi.nih.gov
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unless otherwise stated.domains and recognize the same DNA sequence. How do
the different family members contribute to the complexity
and accuracy of their target genes regulation? To provide
insights to this question, we decided to study the tran-
scriptional regulation of toll-like receptor 3 (TLR3) by the
interferon regulatory factors IRF1 and IRF2 [5]. IRF1 and
IRF2 belong to the nine-member IRF family with highly
homologous N-terminal DNA-binding domains [6-8].
Previous studies suggested that IRF1 is an activator and
IRF2 is a repressor of transcription; and they function an-
tagonistically by recognizing the same DNA motif [9].
TLR3 is a critical regulator of cellular antiviral activ-
ities [10]. It recognizes double-stranded (ds) RNA, which
is an intermediate of viral replication, and transmits sig-
nals to induce the key cytokines of the cellular antiviral
system, the type I interferons IFN-α/β [6]. The expres-
sion of IFN-α/β is activated by NF-κB and TLR3. IFN-α/is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and translocate the trimeric ISGF3 complex consisting
p48, STAT1, and STAT2 to the nucleus, which is re-
quired for the activation of hundreds of target genes
[11]. Both the basal and induced levels of expression of
the interferon-inducible genes are critical for the innate
and activated cellular antiviral activities [12]. Thus un-
derstanding the transcriptional regulation of TLR3 will
provide insights to the cellular antiviral activities. In this
study we present data to show the differential function
of IRF1 and IRF2: IRF2 is associated with TLR3 and
other IFN-inducible gene promoters in unstimulated
states and potentiates their induction in response to viral
infection by maintaining an active chromatin structure
while IRF1 activates transcription of these genes in re-
sponse to viral infection.
Results and discussion
To gain more insight into how the innate and induced
antiviral activities are controlled on gene expression
levels, we studied the molecular mechanisms that con-
trol the expression of the TLR3 gene that is induced by
viral infection. Both the basal level expression and
induction of TLR3 require the chromatin remodeling
activity of the SWI/SNF-like BAF complexes, since the
knockdown of an essential subunit of the complex,
BAF47, severely inhibited its expression [12-15]. To con-
firm that the TLR3 promoter is a direct target site of the
BAF complex, the promoter region [16] was cloned into
pGL3, which does not form regular chromatin structure,
or pREP4 reporter vector, which replicates and forms
regular chromatin structure when transiently transfected
into cells [17]. Co-transfection with BRG1 expression
construct into SW-13 cells, a BRG1-deficient cell line,
significantly activated the promoter with pREP4 vector
but not with the pGL3 vector (Figure 1A), suggesting
that the BAF complex regulates the TLR3 promoter in a
chromatin-dependent manner. Chromatin immunopre-
cipitation (ChIP) assays revealed that anti-BRG1 anti-
body pulled down the endogenous TLR3 promoter
without IFN-α treatment (Figure 1B), indicating the BAF
complex is constitutively associated with the promoter.
IFN-α stimulation enhanced BRG1 binding to the pro-
moter as shown by quantitative-PCR (q-PCR) analysis
(Figure 1B). These results indicate that the TLR3 pro-
moter is a direct target site of the BAF complex.
To identify the DNA elements that mediate the BAF
complex activity, 5′-deletion analysis of the TLR3 pro-
moter was performed. The 509 bp DNA fragment of
promoter was responsive to IFN-α stimulation and to
the BRG1 expression (Figure 1C). Both together can
activated the promoter further. Deletion to −251 reduced
the activity of the promoter. However, the responsiveness
to IFN-α and BRG1 remained, even though an apparentISRE was deleted. Deletion to −11, which removed an
IRF-E sequence, completely abolished the activity of the
promoter. These data suggest that the Sp1 binding site
contributes to and the IRF-E plays an essential role in me-
diating the activity of the BAF complex. Consistent with
this, the point mutation of the Sp1 binding site decreased
the promoter activity, and point mutation of the IRF-E
site completely abolished the activity of the promoter
(Figure 1D). These results are consistent with the obser-
vation that Sp1 stabilizes the BAF complex binding to
target promoters [18].
IRF-E sequence is the binding site for IRFs [19]. ChIP
assays showed that both the IRF1 and IRF2 antibodies
enriched the TLR3 promoter sequence relative to the
control in non-stimulated cells (Figure 2A and B). Inter-
estingly, IFN-α treatment strongly enhanced IRF1 bind-
ing but inhibited IRF2 binding (Figure 2A and B). No
binding was detected for other IRFs (data not shown).
These data suggest that IRF1 and IRF2 may regulate
both the basal and induced expression of the TLR3 gene.
To confirm this, both genes were knocked down by
small interference RNA (siRNA) constructs (Figure 2C).
When IRF1 was knocked down, the induction of the
TLR3 gene (Figure 2D) and its promoter activity (Figure 2E)
were significantly reduced. The basal level expression was
only slightly decreased by siIRF1. Surprisingly, knocking
down IRF2 resulted in a dramatic reduction of both the
basal and induced levels of the TLR3 gene expression and
also its promoter activity (Figure 2D and E). These data re-
veal that while IRF1 is critical for the induction of the TLR3
gene, IRF2 binding to the TLR3 promoter plays an essential
role in both the basal and induced expression of the TLR3
gene in response to interferon stimulation.
Why do the cells take the trouble to make two pro-
teins binding to the same site? We hypothesize that the
TLR3 gene needs to be expressed at low level in the ab-
sence of viral infection and needs to be rapidly induced
to high level in the presence of viral infection. Further-
more, the chromatin structure at the promoter should
be prepared for rapid activation in response to viral in-
fection. Based on the in vivo binding and knock-down
results (Figure 2), we hypothesize that IRF2 may be the
factor to prepare the chromatin structure and direct low
level expression, and IRF1 may be the factor to direct
highly induced expression.
IRF2 has been considered as a transcriptional repres-
sor or activator [5]. To test our hypothesis above, first,
we decided to distinguish if IRF2 is a repressor or weak
activator. When fused to the GAL4 DNA binding do-
main, IRF1 efficiently activated a promoter containing
five GAL4 DNA binding sites, whereas IRF2 showed
only low activity (Figure 3A). These results indicate that
IRF1 is a strong activator and IRF2 is a very weak activa-




Figure 1 IRF-binding site mediates the BAF complex activity at the TLR3 promoter. A The TLR3 promoter is regulated by BAF complex in a
chromatin-dependent manner. SW-13 cells were transfected with the pREP4 or pGL3 reporter vectors in the absence or presence of a BRG1
expression vector for 48 hours. The luciferase activity was analyzed using a dual-luciferase assay kit from Promega. Error bars indicate the range of
three independent experiments. B The BAF complex is associated constitutively with the TLR3 promoter. Chromatin was prepared by sonication
from HeLa cells treated with IFN-α for 12 hours prior to formaldehyde cross-linking. DNA purified from immunoprecipitate with antibody against
BRG1 or pre-immune serum was analyzed with primers covering the TLR3 promoter using quantitative-PCR. C Deletion analysis of the TLR3
promoter. The TLR3 promoter was deleted from 5′ end and analyzed similarly as in panel A. IFN indicates the cells were treated with 500 units/ml
if IFN-α for 12 hours before harvesting for analyzing the luciferase activity. The potential transcription factor binding sites in the promoter region
indicated below the panel. The numbers indicate that the position of deletion and are relative to the transcription initiation site. The Hind III and
Nhe I sites used in the restriction enzyme accessibility assays (Figure 4A) are also indicated. D The IRF-binding site is essential for the TLR3 activity.
The Sp1 and IRF-E sequences in the TLR3 promoter were point-mutated respectively and analyzed as in panel C. wt-TLR3pr: the wild type TLR3
promoter in pREP4-luc reporter vector; MutSp1: the Sp1 binding site in the TLR3 promoter was point-mutated; mutIRF-E: the IRF binding site in
the TLR3 promoter was point-mutated.
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cated that IRF1 protein was highly induced by IFN-α
treatment, with the highest protein level detected after
2 hours of stimulation (Figure 3B). The IRF1 leveldecreased significantly after 8 hours and went back to
basal level at 24 hours post stimulation. In contrast, the
IRF2 protein level was relatively stable (Figure 3B). Re-




Figure 2 IRF1 and IRF2 differentially regulate the basal and induced expression of the TLR3 gene. A IRF1 and IRF2 binding to the TLR3 promoter
in the basal and stimulated states. Chromatin was prepared from HeLa cells with or without IFN-α treatment for 12 hours as in Figure 1B and
subjected to immunoprecipitation using anti-IRF1 and anti-IRF2 antibodies. The ChIP DNA was analyzed using specific primers for the TLR3
promoter or for the control sequence of the β globin gene. B The ChIP DNA in panel A was quantified using real-time PCR analysis. C IRF1 and
IRF2 were knocked down using small interference RNA constructs. HeLa cells were transfected with pREP4-siIRF1 or pREP4-siIRF2. The cells were
harvested after selection with puromycin (1 ug/ml) for 2 days and analyzed by Western blotting. The control is a small interference RNA construct
that failed to knock down IRF1. β actin was used as a protein loading control. D Knocking-down IRF1 and IRF2 inhibits the expression of the TLR3
gene. HeLa cells were transfected with a control, siIRF1, or siIRF2 and selected with puromycin for two days. Following stimulation with IFN-α for
12 hours, total RNAs were isolated and the TLR3 mRNA levels were determined using q-PCR. E Knocking-down IRF1 and IRF2 inhibits the TLR3
promoter activity. pREP4-TLR3pr-luc was co-transfected into HeLa cells with a control, or siIRF1, or siIRF2 construct for 48 hours. Following stimulation
with IFN-α for 12 hours, the cells were harvested and luciferase activity determined as in Figure 1A.
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Figure 3 The binding of IRF1 and IRF2 to the TLR3 promoter is regulated by their protein levels. A IRF1 is a strong activator whereas IRF2 is a
weak activator. A luciferase reporter construct containing five GAL4 DNA binding sites was co-transfected to HeLa cells with a construct expressing
either the GAL4 DNA binding domain-IRF1 fusion or the GAL4 DNA binding domain-IRF2 fusion protein for 48 hours, followed by treatment with
IFN-α for 12 hours. Luciferase activity was measured as in Figure 1A. B IRF2 is expressed constitutively and IRF1 is rapidly induced by IFN-α treatment.
HeLa cells were treated with IFN-α for various times as indicated above the panel. The cells were harvested and analyzed for the protein levels of IRF1,
IRF2, and BRG1 using Western blotting. β actin was used as a loading control. C IRF1 and IRF2 binding to the TLR3 promoter. HeLa cells were treated
with IFN-α for various times as indicated within the panel. ChIP assays were performed and analyzed using q-PCR as in Figure 2A & B. D Over-expression
of IRF1 activated TLR3 promoter. pGL3-TLR3pr-luc was co-transfected with a control vector or IRF1 expression vector, pcDNA4-IRF1 into HeLa cells for
48 hours as indicated below the panel. The luciferase activity was determined as in Figure 1A. E IRF2 is required for induction of IFN-β by polyI/polyC.
HeLa cells transfected with the control or siIRF2 constructs were selected in puromycin for two days. Following treatment with 20 μg/ml of polyI/polyC
for 6 hours, the total RNAs were isolated and analyzed for the presence of IFN-β mRNA by real-time PCR.
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level was detected after 2 hours of IFN-α treatment and
the binding level decreased to almost basal level after
8 hours of stimulation (Figure 3C). These data argue
that the binding levels of IRF1 and IRF2 at the TLR3
promoter are controlled by their relative protein levels in
the cells. If this true, artificially increasing IRF1 level in
the cells would be able to compete with IRF2 and activate
the TLR3 promoter. Indeed, over-expression of IRF1 effi-
ciently activated the TLR3 promoter (Figure 3D), consist-
ent with its ability to compete with IRF2 to bind to the
promoter and its activity as a strong activator.Activation of the TLR3 gene by viral infection or
polyI/polyC leads to the induction of the IFN-β gene,
which is mediated by NF-κB and TLR3 [10]. Our data
that IRF2 is required for the basal and induced levels of
TLR3 expression suggest that knocking down IRF2 may
cripple the cellular response to polyI/polyC. To confirm
this, HeLa cells, which were either transfected with a
control vector or siIRF2, were treated with polyI/polyC.
The induced expression of the IFN-β gene was abolished
by knocking down IRF2 (Figure 3E), suggesting that
IRF2 is a key molecule that controls the cellular antiviral
activities.
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TLR3, we examined the accessibility of the TLR3 pro-
moter to restriction enzyme Hind III, which has a recog-
nition site −39 bp upstream of its TSS. We found that
interferon-α treatment increased the accessibility of the
Hind III site, while no changes were detected at the Nhe
I site which is located at +52, downstream of the TSS
(Figure 4A, lanes 1 and 2). knocking down of BAF47, aA
B
Figure 4 IRF2 is required for chromatin accessibility and active histone mo
the chromatin accessibility at the TLR3 promoter. HeLa cells transfected wi
the panel were selected with puromycin for three days. Following treatme
digested with Hind III for 10 minutes. The purified genomic DNA was dige
specific for the TLR3 promoter. The data were quantified using phosphoim
that of the Nhe I bands and indicated below the panel. The positions of H
H3K4me3 modification at the TLR3 promoter in both unstimulated and stimu
RNA construct targeting IRF2 were selected with puromycin for three days. Fo
prepared and immunoprecipitated with H3K4me3 antibodies. The resulting D
promoter or exon II regions. C IRF2 is required for H3K9ac/K14ac modification
cells transfected with the control or small interference RNA construct targetin
with IFN-α for 12 hours, chromatin fractions were prepared and immunoprec
analyzed using q-PCR with primers for either the TLR3 promoter or exon II regkey subunit of the BAF chromatin remodeling complex,
resulted in decreased accessibility of the Hind III site as
compared to the control Nhe I site (Figure 4A, lanes 3
and 4), consistent with our previous observation that the
BAF complex is involved in the induction of IFN-
inducible genes [12,20]. Interestingly, knocking down of
IRF2 also compromised the accessibility of the Hind III
site (Figure 4A, lanes 5 and 6). These results indicate aC
difications at the TLR3 promoter. A IRF2 and BAF47 are required for
th the control or small interference RNA constructs as indicated above
nt with IFN-α for 12 hours, HeLa nuclei were isolated and briefly
sted to completion with Nhe I and analyzed by LM-PCR using primers
ager analysis. The intensity of the Hind III bands were normalized by
ind III and Nhe I sites were indicated in Figure 1C. B IRF2 is required for
lated states. HeLa cells transfected with the control or small interference
llowing treatment with IFN-α for 12 hours, chromatin fractions were
NA samples were analyzed using q-PCR with primers for either the TLR3
at the TLR3 promoter in both unstimulated and stimulated states. HeLa
g IRF2 were selected with puromycin for three days. Following treatment
ipitated with H3K9ac/K14ac antibodies. The resulting DNA samples were
ions.
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structure at the TLR3 promoter in both non-stimulated
basal and stimulated states.
Next we investigated whether IRF2 binding impacts
histone modifications. Histone H3 is subject to extensive
modifications including acetylation and methylation,
which is correlation with transcriptional activation or
repression [21]. To test whether IRF2 facilitates histone
modifications at the TLR3 promoter, we measured
H3K4me3 and H3K9/K14ac using ChIP assays. Our data
revealed that these modifications at the promoter region
were dramatically decreased by knocking down IRF2,
while no significant changes were detected at the exon II
region of the TLR3 gene (Figure 4B, C). These data con-
firmed our hypothesis that IRF2 is essential for keeping
an open chromatin structure at the TLR3 promoter.
The data that knocking-down IRF2 reduced the chro-
matin accessibility of the TLR3 promoter to a similar
extent as knocking-down BAF47 suggest that IRF2 may
be responsible for the recruitment of the BAF complex
to the promoter in non-stimulated cells. Thus, we per-
formed co-immunoprecipitation assays to test the direct
interaction between IRF2 and the BAF complex. Our data
revealed that BRG1 was co-immunoprecipitated from the
nuclear extracts using both anti-IRF1 and anti-IRF2 anti-
bodies (Figure 5A). Addition of ethidium bromide did
not inhibit the co-immunoprecipitation, indicating that
the interaction was not mediated by DNA. These data
suggest that both IRF1 and IRF2 are capable of recruit-
ing the BAF complex to the TLR3 promoter to maintain
an open chromatin structure through protein-protein
interactions.
IRF1/2 are known to recognize ISRE [22], which medi-
ates the induction of IFN-α target genes by the ISGF3
complex. Since the BAF complex regulates most of the
IFN-α target genes [12], IRF2 may serve as a general re-
cruiter of the BAF complex to the IFN-α target genes.
To test this idea, we analyzed IRF1 and IRF2 binding at
several IFN-α inducible genes by ChIP assays. As shown
in Figure 5B and C, both IRF1 and IRF2 bound to the
promoters of TLR3, IFITM1, IFITM3, and STAT2. Inter-
estingly, IRF2 disappeared from all of these promoters
after IFN-α treatment. We assume that IRF2 was re-
placed by the ISGF3 complex at the IFITM1, IFITM3,
and STAT2 promoters as suggested by the ChIP data
summarized in Figure 5D. Similarly to the induction of
TLR3, knocking down of IRF2 also significantly inhibited
the expression of IFITM1, IFITM3, and STAT2 (Figure 5E).
Therefore, these data define a general role of IRF2 to po-
tentiate the induction of the IFN-α target genes in response
to viral infection.
Recent studies suggested that epigenetic mechanisms
play roles in controlling the function of IRF1 and IRF2
[23]. In particular, histone acetyltransferases can directlyenhance their transcriptional activity by modifying nu-
cleosome or IRFs themselves [24,25]. Our previous stud-
ies suggested that the ATP-remodeling BAF complexes
are required for maintaining the basal and induced ex-
pression of IFN-inducible genes [12]. However, it is not
clear what are the roles of the constitutively expressed
IRFs in this process. Although IRF2 has been considered
a transcriptional repressor and an antagonist of IRF1
[5,26], it has been difficult to explain certain phenotypes
in mice associated with disruption of IRF1 and IRF2
[27,28]. In this study, our data argue against the notion
that IRF2 is a repressor and thus antagonizes the activity
of IRF1. Instead, we demonstrate that IRF1 is a strong
transcription activator and IRF2 is a weak activator,
which act at different stages of TLR3 activation. IRF2
serves two roles at the TLR3 promoter: 1) to recruits the
BAF complex to prepare an open chromatin structure
for rapid activation upon viral infection; 2) to maintain a
basal level expression of the gene for the innate antiviral
activity. IRF1 serves to rapidly activate the promoter by
replacing IRF2 upon induction. However, if the chroma-
tin structure at the promoter was not prepared, induc-
tion completely failed. The functional difference between
IRF1 and IRF2 may arise from two mechanisms. One
is the control of their expression: IRF2 is constitu-
tively expressed while IRF1 is inducible by viral infec-
tion or interferon treatment, which results in different
binding patterns during different stages of cellular
antiviral activity. The other may reflect the differences
of their activation domains: although IRF1’s activation
domain can potently activate transcription, our data
argue that only the activation domain of IRF2 can act
as a pioneering factor to prepare chromatin for rapid
transcription induction in response to stimulation.
Therefore, our data in this report demonstrate that
different members in a transcription factor family are
made to meet different requirements for elaborate tran-
scriptional regulation. The vertebrate organisms gain an




pREP4-TLR3pr-luc, and pGL3-TLR3pr-luc were con-
structed by cloning the PCR-amplified 509 bp fragment
of the TLR3 promoter (from −509 to +1) into appro-
priate restriction sites in the pREP4-luc [17] and pGL3
vectors. The promoter deletion reporter constructs were
generated by cloning the corresponding PCR fragments
in the pREP4-luc vector. The reporter constructs with
point mutations of the Sp1 and IRF-E motifs were gener-
ated from the 509-bp promoter construct using a Strata-
gene mutagenesis kit. The shRNA constructs for IRF1
and IRF2 were generated by inserting the corresponding
AB
C D
Figure 5 (See legend on next page.)
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Figure 5 IRF2 recruits the BAF complex to other IFN target promoters. A IRF1 and IRF2 interact with BAF complex in nuclear extracts. Nuclear
extracts prepared from HeLa cells were immunoprecipitated with the indicated antibodies. The immunoprecipitates were resolved by SDS-PAGE
and blotted with BRG1 antibodies. Two percents of the nuclear extracts used for IP was loaded in lane 1 as input. B Both IRF1 and IRF2 bind to
IFN target promoter without IFN-α stimulation while IRF2 dissociates from IFN target promoters after IFN-α stimulation. ChIP using chromatin from
HeLa cells with or without IFN-α stimulation was performed and analyzed by q-PCR as in Figure 2B. C Interplay of IRFs and ISGF3 at IFN target
promoters. ChIP assays using HeLa cells with or without stimulation with IFN-α for 12 hours were performed. The binding of IRF1, IRF2, p48, and
STAT2 to promoters as indicated was analyzed by q-PCR and the data were summarized. D IRF2 but not IRF1 is required for the basal level activity
of IFN target promoters. Different promoter constructs in pREP4-luc vector as indicated above the columns were co-transfected with the RNA
constructs indicated below the columns into HeLa cells for 48 hours. The luciferase activity was measured as in Figure 1A.
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U6-shBAF47 construct was described previously [12].
The oligonucleotides for Sp1 and IRF-E site mutations
are listed below:
Mutation region Wildtype /Mutation sequences
TLR3-Sp1 motif Wildtype 5’-TTTGATGTgggCGGGTCTGGA-3’
TLR3-Sp1 motif Mutation 5’-TTTGATGTtttCGGGTCTGGA-3’
TLR3-IRF-E motif Wildtype 5’-TCTCGAAagtgaAAGTAAAG-3’
TLR3-Sp1 motif Mutation 5’-TCTCGAAccgacAAGTAAAG-3’
The Oligonucleotides used for shRNA constructs
are listed below:




IRF2 siIRF2#2 5’-ggcaatccatacaggaaagca-3’Antibodies used in this study are from the following
sources
Anti-IRF1(sc-497X; Santa Cruz), anti-IRF2(sc-498X;
Santa Cruz), anti-TLR3(H-125; Santa Cruz), anti-
BRG1(sc-17796X; Santa Cruz), anti-hBRM(sc-6450; Santa
Cruz), anti-BAF47(home made see paper), anti-p48(sc-
496; Santa Cruz), anti-Stat1(06–502; upstate), anti-
Stat2(sc-346-G; Santa Cruz), anti-PloII (sc-899X; Santa
Cruz), anti-CBP(ab10489; abcam), anti-H3K4me3(17–
614; Millipore), anti-H3k9ac/14 ac (ab4441;abcam), anti-
H3(ab1791-100; abcam).Cell culture and transfection
SW-13 cells and HeLa cells were maintained in DMEM
supplemented with 10% fatal calf serum and 1% penicillin-
streptomycin. The THP-1 cells were maintained in
ATCC-formulated RPMI-1640 Medium (Catalog No. 30–
2001) supplemented with 10% fatal calf serum and 1%
penicillin-streptomycin. Transfections of SW-13, HeLa
cells, and THP-1 cells were performed using Superfect
(Qiagen) as instructed by manufacture. The cells were
selected in 1 μg/ml puromycin for 48 hours before stimu-
lation with 500 Units/ml IFN-α for 12 hours for chro-
matin immunoprecipitation and TLR3 gene expression
analysis.RT-PCR analysis
TaqMan® Gene Expression Assays for TLR3 and IFN-β
gene were ordered from ABI (Cat. # Hs01551078_m1;
Cat. # Hs01077958_s1). RT-PCR analyses were performed
as described previously [17], by using total RNAs isolated
from HeLa, SW-13, and THP-1 cells.
ChIP
The chromatin immunoprecipitation assays were formed
as described [18]. For the LTR3 gene promoter region:
Forward primer: 5′-CCGCCCACATCAAATGGT-3′, Re-
verse primer: 5′-GAAAGGGTCACAGATTTAGCAACA-3′,
Probe: 5′-CCCACTTTCAACTTTAG-3′ were used. For the
LTR3 gene extron II region: Forward primer 5′-GTGCA
TCCTCCACCACCAA-3′, Reverse primer 5′-TCGGGTA
CCTGAGTCAACTTCA-3′, and Probe: 5′-TGCACTGT




Probe: 5′-ATCTAGAACCAGAAATACTG-3′ were used.
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